Investigating cardiovascular diseases related to endocrine therapy in hormone receptor-positive early breast cancer: insights from a nationwide real-world study
Open Access
- 9 April 2025
- journal article
- research article
- Published by Springer Nature in Cardio-Oncology
- Vol. 11 (1) , 1-12
Abstract
Breast cancer (BC) patients face abnormal lipid metabolism and increased cardiovascular disease (CVD) risk due to endocrine therapies (ETs). This study evaluates CVD incidence and lipid abnormalities in Chinese patients with early-stage hormone receptor-positive (HR+) BC to inform personalized treatments. Data from female patients aged 18–80 years with stage I-III HR + BC registered in the National Cancer Center Oncology Information Database (NCCOID) (2013–2018) were analyzed. Outcomes included lipid profile changes, CVD incidence, and five-year survival rates. Among 11,537 patients, ETs significantly disrupted lipid metabolism, increasing abnormal total cholesterol, triglycerides, LDL-C, and HDL-C levels. Nonsteroidal aromatase inhibitors (NSAI) ± ovarian function suppression (OFS) led to the largest increase in abnormal total cholesterol (10.26 to 17.32%), while selective estrogen receptor modulators (SERM) ± OFS caused the greatest rises in triglycerides (16.07 to 25.86%), LDL-C (12.11 to 23.34%), and HDL-C (10.86 to 17.23%). Only 3.82% of patients received lipid-lowering therapy. ETs were associated with higher CVD incidence, including hypertension, myocardial infarction, and atrial fibrillation, but five-year survival rates did not differ significantly across ET regimens (P > 0.05). ETs may be associated with alterations in lipid metabolism and a potential increase in CVD risk in early-stage HR + BC patients. These findings highlight the relevance of enhanced lipid monitoring and cardiovascular risk management to support optimized treatment outcomes in the Chinese population.Keywords
This publication has 27 references indexed in Scilit:
- Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting SystemCancer Medicine, 2024
- Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcomeCancer Treatment Reviews, 2023
- Advances in medical treatment of breast cancer in 2022Cancer Innovation, 2023
- The effect of tamoxifen on the lipid profile in women: A systematic review and meta-analysis of randomized controlled trialsExperimental Gerontology, 2022
- Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysisCritical Reviews in Oncology/Hematology, 2020
- Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide dataThe Breast, 2020
- Association between thyroid gland diseases and breast cancer: a case–control studyBreast Cancer Research and Treatment, 2020
- Cardiotoxicity of Aromatase Inhibitors in Breast Cancer PatientsClinical Breast Cancer, 2017
- The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancerEuropean Journal of Cancer, 2016
- Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolismCancer, 2009